Fennec Pharmaceuticals, Inc. (FRX.TO)
14.76
0.00 (0.00%)
CAD |
TSX |
Oct 23, 16:00
Fennec Pharmaceuticals Enterprise Value : 458.58M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 458.58M |
| October 22, 2026 | 458.58M |
| October 21, 2026 | 458.58M |
| October 20, 2026 | 458.58M |
| October 19, 2026 | 428.45M |
| October 16, 2026 | 445.27M |
| October 15, 2026 | 418.64M |
| October 14, 2026 | 448.42M |
| October 13, 2026 | 449.12M |
| October 09, 2026 | 462.08M |
| October 08, 2026 | 462.08M |
| October 07, 2026 | 462.08M |
| October 06, 2026 | 458.23M |
| October 05, 2026 | 445.97M |
| October 02, 2026 | 449.82M |
| October 01, 2026 | 460.68M |
| September 30, 2026 | 482.05M |
| September 29, 2026 | 482.05M |
| September 28, 2026 | 482.05M |
| September 25, 2026 | 468.39M |
| September 24, 2026 | 468.39M |
| September 23, 2026 | 477.15M |
| September 22, 2026 | 466.99M |
| September 21, 2026 | 466.99M |
| September 18, 2026 | 466.99M |
| Date | Value |
|---|---|
| September 17, 2026 | 469.79M |
| September 16, 2026 | 457.18M |
| September 15, 2026 | 450.52M |
| September 14, 2026 | 540.56M |
| September 11, 2026 | 540.56M |
| September 10, 2026 | 540.56M |
| September 09, 2026 | 540.56M |
| September 08, 2026 | 540.56M |
| September 04, 2026 | 551.77M |
| September 03, 2026 | 547.22M |
| September 02, 2026 | 537.06M |
| September 01, 2026 | 537.06M |
| August 31, 2026 | 537.06M |
| August 28, 2026 | 537.06M |
| August 27, 2026 | 537.06M |
| August 26, 2026 | 537.06M |
| August 25, 2026 | 484.15M |
| August 24, 2026 | 484.15M |
| August 21, 2026 | 484.15M |
| August 20, 2026 | 489.06M |
| August 19, 2026 | 515.33M |
| August 18, 2026 | 537.41M |
| August 17, 2026 | 537.41M |
| August 14, 2026 | 537.41M |
| August 13, 2026 | 537.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bright Minds Biosciences, Inc. | 414.88M |
| Spectral Medical, Inc. | 317.48M |
| Resverlogix Corp. | 139.42M |
| Theratechnologies, Inc. | -- |
| COSCIENS Biopharma, Inc. | 4.436M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.731M |
| Revenue (Quarterly) | 24.74M |
| Total Expenses (Quarterly) | 22.01M |
| EPS Diluted (Quarterly) | 0.075 |
| Gross Profit Margin (Quarterly) | 95.97% |
| Profit Margin (Quarterly) | 11.04% |
| Earnings Yield | -1.21% |
| Normalized Earnings Yield | -0.7825 |